TSHA vs. AMPH, INDV, DYN, ARDX, EVO, ANIP, IOVA, OCUL, ARVN, and CALT
Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Amphastar Pharmaceuticals (AMPH), Indivior (INDV), Dyne Therapeutics (DYN), Ardelyx (ARDX), Evotec (EVO), ANI Pharmaceuticals (ANIP), Iovance Biotherapeutics (IOVA), Ocular Therapeutix (OCUL), Arvinas (ARVN), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.
Taysha Gene Therapies vs.
Taysha Gene Therapies (NASDAQ:TSHA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
Amphastar Pharmaceuticals has a net margin of 21.80% compared to Taysha Gene Therapies' net margin of -229.67%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Taysha Gene Therapies' return on equity.
In the previous week, Taysha Gene Therapies had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 4 mentions for Amphastar Pharmaceuticals. Taysha Gene Therapies' average media sentiment score of 0.64 beat Amphastar Pharmaceuticals' score of 0.43 indicating that Taysha Gene Therapies is being referred to more favorably in the media.
77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 2.7% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Taysha Gene Therapies currently has a consensus target price of $6.63, indicating a potential upside of 270.11%. Amphastar Pharmaceuticals has a consensus target price of $45.50, indicating a potential upside of 64.32%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, research analysts clearly believe Taysha Gene Therapies is more favorable than Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals received 285 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 77.54% of users gave Taysha Gene Therapies an outperform vote while only 66.10% of users gave Amphastar Pharmaceuticals an outperform vote.
Taysha Gene Therapies has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Amphastar Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Taysha Gene Therapies and Amphastar Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Taysha Gene Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taysha Gene Therapies Competitors List
Related Companies and Tools
This page (NASDAQ:TSHA) was last updated on 3/17/2025 by MarketBeat.com Staff
Free TSHA Stock Alerts